Landos Biopharma

Landos Biopharma: Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases that are the first to target new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Lead asset omilancor is a novel, oral, gut-restricted small molecule therapeutic candidate for the treatment of ulcerative colitis, Crohn’s disease and Eosinophilic Esophagitis that targets the LANCL2 pathway (UC Ph2 complete in 2021, initiating Ph3 in 2H21, Crohn's Ph2 initiated 1H21). NX-13 is a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway (UC Ph1b initiated 2Q21). Additional candidates are in development for the treatment of lupus nephritis, rheumatoid arthritis, multiple sclerosis, and diabetes. Partnership with LianBio to develop and commercialize Omilancor and NX-13 in greater China and select Asian markets announced May 2021.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - South Atlantic
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Gastrointestinal, Metabolic Disorders
Listing
Public, USA
Market Cap
100MM - 500MM
Website:
Profiles:
Address:
1800 Kraft Drive SW
Suite 216
Blacksburg, VA 24060
United States

Company Participants at Solebury Trout Virtual Management Access Event - 1x1 conference calls

  • Josep Bassaganya-Riera, Chairman of the Board, President & CEO

Lead Programs

BT-11

Indication Phase
LANCL2 2
LANCL2 1

NX-13

Indication Phase
NLRX1 IND
NLRX1 IND

BT-104

Indication Phase
LANCL2 Pre-clinical
LANCL2 Pre-clinical

Top 10 Holders of Landos Biopharma, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Perceptive Advisors LLC 45.86 17,960,839 217.15 Stakes 3/31/21
RTW Investments LP 10.92 4,275,722 51.69 13F 3/31/21
Logos Global Management LP 1.87 734,000 8.87 13F 3/31/21
OrbiMed Advisors LLC 1.74 681,000 8.23 13F 3/31/21
Deerfield Management Company LP 1.15 450,000 5.44 13F 3/31/21
JPMorgan Investment Management, Inc. 0.87 340,473 4.12 13F 3/31/21
Woodline Partners LP 0.54 213,335 2.58 13F 3/31/21
The Vanguard Group, Inc. 0.45 181,867 2.20 Funds 4/30/21
Vanguard Group, Inc. (Subfiler) 0.45 176,409 2.13 13F 3/31/21
BlackRock Fund Advisors 0.45 175,260 2.12 13F 3/31/21
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.